Response
Blair et al insightfully critique our recent publication, 1 highlighting several issues. Foremost is referral/ascertainment bias in our study cohort. Indeed, the hypertrophic cardiomyopathy (HCM) literature is filled with biases, from the breakthrough linkage studies defining HCM as a sarcomeric disease (based on large families with highly penetrant disease) to our study of tertiary referral center HCM. Blair et al emphasize that our cohort is overrepresented by patients with obstructive HCM and myectomy, stating that it was "inevitable" that mutations would be identified in individuals with severe disease. Although the former is true, the average age of our cohort is 41 years, half are asymptomatic, and three fourths have no family history of sudden death, challenging the "inevitability" of severe disease expression. We previously found that only 3 of these 293 patients had a "malignant" mutation, 2 prompting the search for "benign" mutations.
Blair et al recommend analysis of all mutation-positive family members, exclusive of probands. That study design was used to assign mutations as "malignant" or "benign." However, our goal was to determine whether these previous assignments are predictive in an unrelated cohort of patients who do not share genetic and environmental modifiers.
We agree that to focus on "the individual patient" without considering family history would be misguided. Family history is sought meticulously in our HCM Clinic and was found to be substantial rather than "scanty." We determined that 32% of probands had a positive family history of HCM in a first-degree relative (offspring, siblings, and/or parents).
As Blair et al correctly assert, each specific HCM-causing mutation is rare. 3 Our cohort underscores this fact. Although HCM research laboratories clearly understand the implications of this genetic heterogeneity, genetic testing for specific prognostic mutations continues to be advocated, and the notion persists that some mutations are "common." Here, our work clarifies the situation for those unfamiliar with the field.
Finally, Blair et al highlight the profound effect of compound heterozygosity. Certainly the presence of multiple mutations may contribute to the severe disease seen in these 5 patients. Comprehensive analysis of all HCM-causing genes is underway. However, in 20% or more cases of HCM, no mutation can be identified in any of the 10 known HCM-causing genes. Until all HCM-causing genes are identified, it may be challenging to determine the precise relative risk contributed by a specific mutation.
